Skip to content
MarketScale
‹ Back to IndustriesSciences

The Secret Science To Harnessing the Power of Probiotics using Prebiotics

Whether you prefer yogurt, kimchi, kefir, or kombucha, probiotics are all around us. But how do we really harness the benefits of this good bacteria, and capitalize on consuming foods that keep us healthy? The answer — Prebiotics. Tackling the science, consumer habits, and marketing behind prebiotics in this episode of the MarketScale Sciences…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · Daniel Litwin PodcastJohn Davidson PodcastJohn Deaton PodcastPromoted Content
Share

Key takeaways

01

Whether you prefer yogurt, kimchi, kefir, or kombucha, probiotics are all around us.

02

But how do we really harness the benefits of this good bacteria, and capitalize on consuming foods that keep us healthy?

03

Tackling the science, consumer habits, and marketing behind prebiotics in this episode of the MarketScale Sciences…

Whether you prefer yogurt, kimchi, kefir, or kombucha, probiotics are all around us. But how do we really harness the benefits of this good bacteria, and capitalize on consuming foods that keep us healthy? The answer — Prebiotics.

Tackling the science, consumer habits, and marketing behind prebiotics in this episode of the MarketScale Sciences Podcast are scientists John Davidson, Director of Innovation & Education for Deerland Probioics & Enzymes, and John Deaton, VP of Science & Technology for Deerland Probiotics & Enzymes. This episode talks about how and why it is important to prime your gut with prebiotics, in order to truly harness the power of probiotics. From a marketing standpoint “probiotics were first out of the gate,” Deaton says, “but it’s not as simple as consuming a probiotic.”

Probiotic organisms are not very shelf-stable, nor very resilient to our stomach acids. This is why a prebiotic is so important. As non-living organisms, prebiotics are a food source or a compound, and much easier to manage in application. But, for real efficacy, prebiotics must be consumed in large doses. Herein lies the crux that Deerland has tackled head-on.

How do we provide a prebiotic that is small, consumable, and reduces the main side effect of gas, caused by fermentation in the gut? Davidson explains the groundbreaking science of their prebiotic, which is “based on bacteria phase technology.” Davidson and Deaton have reduced the dosage of necessary prebiotics from over 1 gram, to “Only 15 mg a day required for efficacy.”

In short, Deerland has “Really revolutionized the whole prebiotic space.” Says Davidson. The science is in, but the hard work isn’t over. “Consumer education is gonna be the key,” says Davidson. Consumers may love the idea of probiotics, but don’t know that their efforts are futile without the symbiotic help of prebiotics.

Luckily, the probiotic and prebiotic markets are only growing, with business owners taking note of this health phenomenon. Deerland Probiotics & Enzymes is ready with their prebiotic solution, PreforPro.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512